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Abstract: Yaws is one of the three endemic treponematoses and is recognised by the World Health
Organization as a neglected tropical disease. Yaws is currently reported in 15 countries in the
Pacific, South-East Asia, West and Central Africa, predominantly affects children, and results in
destructive lesions of the skin and soft tissues. For most of the twentieth century penicillin-based
treatment was the standard of care and resistance to penicillin has still not been described.
Recently, oral azithromycin has been shown to be an effective treatment for yaws, facilitating renewed
yaws eradication efforts. Resistance to azithromycin is an emerging threat and close surveillance will
be required as yaws eradication efforts are scaled up globally.
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1. Introduction
Yaws, caused by Treponema pallidum subsp. pertenue, is one of the three endemic treponematoses
(along with T.p. subsp. endemicum, the causative agent of bejel, and T. carateum, the causative agent of
pinta) and is recognised by the World Health Organization as a neglected tropical disease (NTD) [1,2].
The disease predominantly affects children and results in destructive lesions of the skin and soft
tissues. Yaws is still found in Africa, South-East Asia and the Pacific. T.p. subsp. pertenue is closely
related to T.p. subsp. pallidum, the causative agent of syphilis [3] but neither sexual nor mother-to-child
transmission of yaws is believed to occur [2].
2. Epidemiology
Yaws is currently reported in 15 countries in the Pacific, South-East Asia, West and Central
Africa [4–9]. Currently the most cases are reported in Papua New Guinea, the Solomon Islands
and Ghana and all have reported in excess of 15,000 cases in recent years. In the mid-twentieth
century, yaws was endemic in South America and the Caribbean, but control programmes in the
mid-twentieth century (see below) are believed to have eliminated yaws from the majority of countries
in the region [10,11]. India interrupted transmission in 2004 and declared elimination in 2006 [12]
following a sustained programme that began in 1996.
Yaws is restricted to warm and humid environments [13]. Transmission is skin to skin contact from
active infectious lesions [14]. Early studies had suggested that flies may play a role in transmission
but there is no definitive proof that this occurs [14–16]. The majority of active infections cases occur in
children aged under 15 years. Closely-related treponemal infections have been identified in primate
populations, but zoonotic transmission to humans has not been established [17,18].
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3. Clinical Features
As with other treponemal infections, yaws is characterized by a multi-stage disease process
predominantly involving skin, bones and cartilage.
The initial stage of primary yaws is the development of an erythematous lesion that occurs at
the site of inoculation after an incubation period of 9–90 days [14,19]. These lesions may break down
forming an ulcerated plaque over a period of 1–2 weeks. Primary lesions occur most frequently on the
lower limbs or buttocks [13,20], whilst genital lesions are extremely uncommon. If patients are left
untreated then primary lesions will heal spontaneously, with scarring, over a period of 3–6 months [21].
Without treatment individuals will progress to secondary yaws. Secondary yaws predominantly
involves the skin and bones [20,22]. As with secondary syphilis, both generalised lymphadenopathy
and constitutional symptoms, including fever and malaise, are frequently reported in patients with
secondary yaws [19]. A wide-range of skin manifestations occur in secondary yaws including macular
lesions and hyperkeratotic lesions on the palms and soles (‘crab yaws’) [14,19,20]. Osteoperiostitis,
affecting the fingers (resulting in dactylitis) or long bones (forearm, fibula, tibula) is the most common
bony manifestation of secondary yaws. Following treatment of early yaws (primary or secondary) skin
lesions usually resolve within 2–4 weeks and bone pain may start to resolve in as little as 48 h [23].
In the absence of treatment of early yaws, patients go on to develop latent infection. During this
clinical stage of disease patients have reactive serology but no clinical evidence of infection.
Relapse from latent to active disease can occur for a period of up to 5–10 years and serve as a source
of onward transmission. Previously up to 10% of patients were reported to develop the late-stage
manifestations of tertiary yaws, but this is now much less commonly reported [19]. Tertiary disease
may manifest as gummatous nodules resulting in tissue necrosis, a destructive osteitis which can cause
destruction of the maxilla (gangosa), or bowing of the shins (sabre shin), or a hypertrophic periostitis
causing exostosis of the paranasal maxilla (gondou).
Clinical diagnosis is supported by serological testing. Diagnostic testing combines a treponemal
assay (such as the Treponema pallidum particle agglutination assay) and a non-treponemal assay (such
as the rapid plasma regain assay). Treponemal tests are more specific but remain positive for life.
The titre of non-treponemal assays rises following infection and falls following treatment. A four-fold
fall in titre (e.g., from 1:16 to 1:4) is considered consistent with serological cure. Newer point-of-care
treponemal and non-treponemal assays have increasingly taken on the role of traditional lab-based
assays [24,25].
An important recent discovery has been the finding that Haemophilus ducreyi may cause ulcerative
skin lesions similar to those seen in patients with early yaws [26,27]. H. ducreyi may cause lesions
in both patients who have non-reactive and reactive serological tests for yaws, which complicates
assessment of patients with suspected active yaws as serological point of care tests cannot be used to
accurately provide a definitive diagnosis. When molecular tests are used, a large proportion of patients
suspected to have active early yaws are found in fact to have latent yaws (reactive serological tests)
and a different cause for the current skin lesion.
4. Penicillin-Based Treatment
Early studies conducted in Haiti demonstrated that penicillin-based treatments were highly
efficacious in the treatment of yaws [23] and penicillin-based therapy was subsequently adopted as the
standard of care worldwide for all endemic treponematoses [14]. Different penicillin-based regimes
are effective for the treatment of yaws, but long-acting intramuscular benzathine benzylpenicillin was
the most commonly used regimen. Lower doses were used than those recommended for the treatment
of venereal syphilis (1.2 million units for the treatment of adults and 0.6 million units for the treatment
of children) [14]. Although there have been rare reports of ‘treatment failure’ with penicillin-based
therapy, the inability to distinguish treatment failure from reinfection makes these data extremely
difficult to interpret, especially in highly endemic settings [28]. As with syphilis, no evidence of
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penicillin resistance has developed in yaws despite it being the first-line treatment for more than
50 years.
During the mid-twentieth century, successful treatment campaigns were conducted targeting yaws
and the other endemic treponematoses [29]. In 1949, the World Health Assembly passed a resolution
supporting efforts for the control and elimination of the endemic treponematoses, including yaws.
WHO and UNICEF led a global effort between 1952 and 1964, based on penicillin treatment. At the
time, the recommended strategy varied, based on the prevalence of active yaws in the community
(Table 1). Although not ultimately successful in achieving eradication, the programme did significantly
reduce the global prevalence of yaws by as much as 98% [30]. Following these efforts, the incidence of
the disease rebounded in a number of countries in the 1970s, ultimately leading to a further World
Health Assembly resolution in 1978, which resulted in some countries renewing control efforts [29].
Table 1. Historical strategy for the eradication of yaws: 1952–1964.
Prevalence of Clinically Active Yaws Treatment Strategy
Hyperendemic: above 10% Benzathine benzylpenicillin to the whole community(total mass treatment)
Mesoendemic: 5–10%
Treat all active cases, all children under 15 and all contacts
of infectious cases
(juvenile mass treatment)
Hypoendemic: under 5% Treat all active cases and all household and other contacts(selective mass treatment)
5. Azithromycin-Based Treatment
Despite its efficacy, treatment with penicillin remains challenging in many settings. Injectable
penicillin requires access to a secure cold chain and trained staff to administer therapy, both of which
are not always available in the remote locations where yaws is found. Treatment also carried a small
but important risk of anaphylaxis. Supplies of benzathine benzylpenicillin have also been insecure in
recent years [31], with implications for reliable access to treatment.
Azithromycin, an oral macrolide antibiotic, had previously been demonstrated to be effective
in the treatment of syphilis [32] with cure rates equivalent to those of benzathine benzylpenicillin.
Given the high degree of genetic homology between syphilis and yaws, azithromycin was an attractive
option for study as an alternative treatment for yaws. In a landmark study conducted in Papua New
Guinea, patients with early (primary and secondary) yaws were randomised to receive treatment with
either a single dose of intramuscular benzathine benzylpenicillin or a single, oral dose of azithromycin.
Azithromycin was shown to be non-inferior to benzathine benzylpenicillin with a cure rate greater than
95% in both arms [33]. Subsequently, a study conducted in Ghana also confirmed the non-inferiority of
azithromycin compared to benzathine benzylpenicillin [34].
These initial studies all enrolled patients with early active yaws and used a dose of 30 mg/kg
(max. 2 g). Two outstanding questions were whether azithromycin was effective for the treatment
of latent infection and whether the lower dose of azithromycin used for the treatment of trachoma
(20 mg/kg—max. 1 g) was also efficacious in the treatment of yaws. In a longitudinal cohort study in
Papua New Guinea, treatment with azithromycin was demonstrated to have a cure rate for patients
with latent yaws equivalent to the cure rate of patients with active yaws [35]. The efficacy of the low
versus standard dose azithromycin was compared in a randomised control trial in patients with both
early active and latent yaws, conducted in Papua New Guinea and Ghana. The clinical cure rate was
equivalent in both low and standard dose arms. The serological cure rate in patients with active yaws
was slightly lower in the low-dose arm. In patients with latent yaws the serological cure rate was
equivalent with both doses of azithromycin [36]. Taken together with observational data, this suggests
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that low-dose azithromycin is also effective in the treatment of yaws, although the 30 mg/kg dose
remains the standard of care.
Unlike with penicillin, resistance to azithromycin is well described in T. pallidum. Resistance is
mediated by one of two mutations in the 23s rDNA and can be detected by specific molecular
tests [37–41]. In the context of large scale azithromycin-based treatment programmes (see below),
treatment failure and genotypic resistance to azithromycin has now also been described in yaws [42].
6. Community Treatment with Azithromycin
Azithromycin has been widely distributed at the community level for the treatment of
trachoma [43] and the WHO recommends mass drug administration (MDA) of azithromycin for
the elimination of trachoma as a public health problem as part of the SAFE (Surgery, Antibiotics,
Facial cleanliness and Environmental improvement) strategy [44]. MDA of azithromycin has been
shown to be safe and indeed there is considerable evidence that MDA may result in significant
off-target benefits including reductions in child mortality [45].
Taken together, the evidence of the safety of MDA with azithromycin and the efficacy of
azithromycin for the treatment of yaws provide the rationale behind the revised WHO strategy
for the eradication of yaws (the Morges strategy). This strategy emphasises MDA of azithromycin
in communities where yaws is endemic. Following an initial round of MDA (referred to as total
community treatment—TCT) it may be appropriate to conduct further MDA or to switch to a strategy
of treating active cases and their contacts (total targeted treatment—TTT) [46]. No clear evidence
currently exists to guide the decision regarding when to switch between TCT and TTT, but modelling
studies suggest that TCT is a preferable strategy because it ensures a higher coverage of latent yaws
cases [47,48].
Initial assessments of the efficacy of azithromycin MDA were conducted in both the Pacific and
West Africa. In a study in the Solomon Islands, communities received a single round of MDA of
azithromycin (conducted for the elimination of trachoma as a public health problem) at a dose of
20 mg/kg (max. 1g) and were followed up at 6 and 18 months following MDA [49–51]. A significant
reduction in the prevalence of both active and latent yaws was seen at both 6 and 18 months following
MDA. In Ghana, MDA with azithromycin (30 mg/kg, max. 2 g) was conducted in a single district and
follow-up conducted at 12 months. As in the Solomon Islands, a significant reduction in both active
and latent yaws was documented [52].
The most comprehensive evaluation of the WHO Morges strategy was conducted in Lihir,
Papua New Guinea [53]. In this study of more than 15,000 individuals, an initial round of mass
treatment was undertaken, followed by six-monthly rounds of surveillance and treatment of new cases
and their contacts. In keeping with the studies discussed above, this study demonstrated a marked
reduction in the prevalence of both active and latent yaws. Despite this initial success, interruption of
transmission was not achieved [42]. Ongoing transmission was driven both by cases imported from
outside the study site and cases arising in individuals missed during the initial mass treatment phase of
the study. Thirty-six months into the study, a single case of treatment failure was detected. The patient
had been treated at 30 months with azithromycin but at month 36 had clinical evidence of progression
and serological evidence of treatment failure. Subsequent molecular testing confirmed genotypic
azithromycin resistance in this case. Alongside the index case, several contacts were detected at month
36 and month 42 of the study with azithromycin-resistant yaws. Although subsequent treatment with
benzathine benzylpenicillin was used to successfully ring-fence the outbreak, these data highlight the
risk of emerging azithromycin resistance threatening yaws eradication efforts [42].
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7. Conclusions
There has been considerable progress in the treatment of yaws in the last decade. Azithromycin
has emerged as an effective and easily deliverable oral treatment option that can be used to treat both
individual cases and during community MDA. The emergence of azithromycin resistance highlights
the need for ongoing surveillance to support yaws eradication efforts globally. Further studies are
needed to better define the optimum MDA strategy including the number of rounds and population
coverage required to interrupt the transmission of yaws.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Marks, M.; Solomon, A.W.; Mabey, D.C. Endemic treponemal diseases. Trans. R. Soc. Trop. Med. Hyg. 2014,
108, 601–607. [CrossRef] [PubMed]
2. Mitjà, O.; Asiedu, K.; Mabey, D. Yaws. Lancet 2013, 381, 763–773. [CrossRef]
3. Cejková, D.; Zobaníková, M.; Chen, L.; Pospíšilová, P.; Strouhal, M.; Qin, M.; Mikalová, L.; Norris, S.J.;
Muzny, D.M.; Gibbs, R.A.; et al. Whole genome sequences of three Treponema pallidum ssp. pertenue strains:
Yaws and syphilis treponemes differ in less than 0.2% of the genome sequence. PLoS Negl. Trop. Dis. 2012,
6, e1471.
4. Agadzi, V.K.; Aboagye-Atta, Y.; Nelson, J.W.; Perine, P.L.; Hopkins, D.R. Resurgence of yaws in Ghana.
Lancet 1983, 2, 389–390. [CrossRef]
5. Asiedu, K. The return of yaws. Bull. World Health Organ. 2008, 86, 507–508. [PubMed]
6. Tharmaphornpilas, P.; Srivanichakorn, S.; Phraesrisakul, N. Recurrence of yaws outbreak in Thailand, 1990.
Southeast Asian J. Trop. Med. Public Health 1994, 25, 152–156. [PubMed]
7. Fegan, D.; Glennon, M.; Macbride-Stewart, G.; Moore, T. Yaws in the Solomon Islands. J. Trop. Med. Hyg.
1990, 93, 52–57. [PubMed]
8. Fegan, D.; Glennon, M.J.; Thami, Y.; Pakoa, G. Resurgence of yaws in Tanna, Vanuatu: Time for a new
approach? Trop. Doct. 2010, 40, 68–69. [CrossRef] [PubMed]
9. Manning, L.A.; Ogle, G.D. Yaws in the periurban settlements of Port Moresby, Papua New Guinea. Papua New
Guinea Med. J. 2002, 45, 206–212.
10. John, R.K.S. Yaws in the Americas. Rev. Infect. Dis. 1985, 7, S266–S272. [CrossRef]
11. Scolnik, D.; Aronson, L.; Lovinsky, R.; Toledano, K.; Glazier, R.; Eisenstadt, J.; Eisenberg, P.; Wilcox, L.;
Rowsell, R.; Sliverman, M. Efficacy of a targeted, oral penicillin-based yaws control program among children
living in rural South America. Clin. Infect. Dis. 2003, 36, 1232–1238. [CrossRef] [PubMed]
12. Bora, D.; Dhariwal, A.C.; Lal, S. Yaws and its eradication in India—A brief review. J. Commun. Dis. 2005,
37, 1–11. [PubMed]
13. Hackett, C.J. Extent and nature of the yaws problem in Africa. Bull. World Health Organ. 1953, 8, 127–182.
14. Perine, P.L.; Hopkins, D.R.; Niemel, P.L.A.; St.-John, R.; Causse, G.; Antal, G.M. Handbook of Endemic
Treponematoses: Yaws, Endemic Syphilis and Pinta; World Health Organization: Geneva, Switzerland, 1984;
Available online: http://apps.who.int/iris/handle/10665/37178?locale=en (accessed on 2 May 2013).
15. Houinei, W.; Godornes, C.; Kapa, A.; Knauf, S.; Mooring, E.Q.; González-Beiras, C.; Watup, R.; Paru, R.;
Advent, P.; Bieb, S.; et al. Haemophilus ducreyi DNA is detectable on the skin of asymptomatic children, flies
and fomites in villages of Papua New Guinea. PLoS Negl. Trop. Dis. 2017, 11, e0004958. [CrossRef] [PubMed]
16. Knauf, S.; Raphael, J.; Mitjà, O.; Lejora, I.A.V.; Chuma, I.S.; Batamuzi, E.K.; Keyyu, J.D.; Fyumagwa, R.;
Lüert, S.; Godornes, C.; et al. Isolation of Treponema DNA from necrophagous flies in a natural ecosystem.
EBioMedicine 2016, 11, 85–90. [CrossRef] [PubMed]
17. Harper, K.N.; Fyumagwa, R.D.; Hoare, R.; Wambura, P.N.; Coppenhaver, D.H.; Sapolsky, R.M.; Alberts, S.C.;
Tung, J.; Rogers, J.; Kilewo, M.; et al. Treponema pallidum infection in the wild baboons of East Africa:
Distribution and genetic characterization of the strains responsible. PLoS ONE 2012, 7, e50882. [CrossRef]
[PubMed]
Trop. Med. Infect. Dis. 2018, 3, 92 6 of 7
18. Knauf, S.; Liu, H.; Harper, K.N. Treponemal infection in nonhuman primates as possible reservoir for human
yaws. Emerg. Infect. Dis. 2013, 19, 2058–2060. [CrossRef] [PubMed]
19. Koff, A.B.; Rosen, T. Nonvenereal treponematoses: Yaws, endemic syphilis, and pinta. J. Am. Acad. Dermatol.
1993, 29, 519–535. [CrossRef]
20. Mitjà, O.; Hays, R.; Lelngei, F.; Laban, N.; Ipai, A.; Pakarui, S.; Bassat, Q. Challenges in recognition and
diagnosis of yaws in children in Papua New Guinea. Am. J. Trop. Med. Hyg. 2011, 85, 113–116. [CrossRef]
[PubMed]
21. Sehgal, V.N. Leg ulcers caused by yaws and endemic syphilis. Clin. Dermatol. 1990, 8, 166–174. [CrossRef]
22. Mitjà, O.; Hays, R.; Ipai, A.; Wau, B.; Bassat, Q. Osteoperiostitis in early yaws: Case series and literature
review. Clin. Infect. Dis. 2011, 52, 771–774. [CrossRef] [PubMed]
23. Rein, C.R. Treatment of yaws in the Haitian peasant. J. Natl. Med. Assoc. 1949, 41, 60–65. [PubMed]
24. Marks, M.; Goncalves, A.; Vahi, V.; Sakana, O.; Puiahi, E.; Zhang, Z.; Dalipanda, T.; Bottomley, C.; Mabey, D.;
Solomin, A.W. Evaluation of a rapid diagnostic test for yaws infection in a community surveillance setting.
PLoS Negl. Trop. Dis. 2014, 8, e3156. [CrossRef] [PubMed]
25. Ayove, T.; Houniei, W.; Wangnapi, R.; Bieb, S.V.; Kazadi, W.; Luke, L.N.; Manineng, C.; Moses, P.; Paru, R.;
Esfandiari, J.; et al. Sensitivity and specificity of a rapid point-of-care test for active yaws: A comparative
study. Lancet Glob. Health 2014, 2, e415–e421. [CrossRef]
26. Marks, M.; Chi, K.H.; Vahi, V.; Pillay, N.; Sokana, O.; Pavluck, A.; Mabey, D.C.; Chen, C.Y.; Solomon, A.W.
Haemophilus ducreyi associated with skin ulcers among children, Solomon Islands. Emerg. Infect. Dis. 2014,
20, 1705–1707. [CrossRef] [PubMed]
27. Mitjà, O.; Lukehart, S.A.; Pokowas, G.; Moses, P.; Kapa, A.; Godones, C.; Robson, J.; Cherian, S.; Houinei, W.;
Kazadi, W.; et al. Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua
New Guinea: A prospective cohort study. Lancet Glob. Health 2014, 2, e235–e241. [CrossRef]
28. Backhouse, J.L.; Hudson, B.J.; Hamilton, P.A.; Nesteroff, S.I. Failure of penicillin treatment of yaws on Karkar
Island, Papua New Guinea. Am. J. Trop. Med. Hyg. 1998, 59, 388–392. [CrossRef] [PubMed]
29. Asiedu, K.; Amouzou, B.; Dhariwal, A.; Karam, M.; Lobo, D.; Patnaik, S.; Meheus, A. Yaws eradication: Past
efforts and future perspectives. Bull. World Health Organ. 2008, 86, 499. [CrossRef] [PubMed]
30. Antal, G.M.; Causse, G. The control of endemic treponematoses. Rev. Infect. Dis. 1985, 7, S220–S226.
[CrossRef] [PubMed]
31. Nurse-Findlay, S.; Taylor, M.M.; Savage, M.; Mello, M.B.; Saliyou, S.; Lavayen, S.; Seghers, F.; Campbell, M.L.;
Birgirimana, F.; Ouedraogo, L.; et al. Shortages of benzathine penicillin for prevention of mother-to-child
transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews. PLoS Med.
2017, 14, e1002473. [CrossRef] [PubMed]
32. Riedner, G.; Rusizoka, M.; Todd, J.; Maboko, L.; Hoelscher, M.; Mmbando, D.; Samky, E.; Lyamuya, E.;
Mabey, D.; Grosskurth, H.; et al. Single-dose azithromycin versus penicillin G benzathine for the treatment
of early syphilis. N. Engl. J. Med. 2005, 353, 1236–1244. [CrossRef] [PubMed]
33. Mitjà, O.; Hays, R.; Ipai, A.; Penias, M.; Paru, R.; Fagaho, D.; Lazzari, E.; Bassat, Q. Single-dose azithromycin
versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: An open-label,
non-inferiority, randomised trial. Lancet 2012, 379, 342–347.
34. Kwakye-Maclean, C.; Agana, N.; Gyapong, J.; Nortey, P.; Adu-Sarkodie, Y.; Aryee, E.; Asiedu, K.; Ballard, R.;
Binka, F. A single dose oral azithromycin versus intramuscular benzathine penicillin for the treatment of
yaws—A randomized non-inferiority trial in Ghana. PLoS Negl. Trop. Dis. 2017, 11, e0005154. [CrossRef]
[PubMed]
35. Mitjà, O.; González-Beiras, C.; Godornes, C.; Kolmau, R.; Houinei, W.; Abel, H.; Kapa, A.; Paru, A.; Bieb, S.V.;
Wangi, J.; et al. Effectiveness of single-dose azithromycin to treat latent yaws: A longitudinal comparative
cohort study. Lancet Glob. Health 2017, 5, e1268–e1274.
36. Marks, M.; Mitjà, O.; Bottomley, C.; Kwakye, C.; Houinei, W.; Bauri, M.; Adwere, P.; Abdulai, A.A.; Dua, F.;
Boateng, L.; et al. Comparative efficacy of low-dose versus standard-dose azithromycin for patients with
yaws: A randomised non-inferiority trial in Ghana and Papua New Guinea. Lancet Glob. Health 2018,
6, e401–e410. [CrossRef]
37. Grimes, M.; Sahi, S.K.; Godornes, B.C.; Tantalo, L.C.; Roberts, N.; Bostick, D.; Marra, C.M.; Lukehart, S.A. Two
mutations associated with macrolide resistance in Treponema pallidum: Increasing prevalence and correlation
with molecular strain type in Seattle, Washington. Sex Transm. Dis. 2012, 39, 954–958. [CrossRef] [PubMed]
Trop. Med. Infect. Dis. 2018, 3, 92 7 of 7
38. Lukehart, S.A.; Godornes, C.; Molini, B.J.; Sonnett, P.; Hopkins, S.; Mulcahy, F.; Engelman, J.; Mitchell, S.J.;
Rompalo, A.M.; Marra, C.M.; et al. Macrolide resistance in Treponema pallidum in the United States and
Ireland. N. Engl. J. Med. 2004, 351, 154–158. [CrossRef] [PubMed]
39. Chen, C.Y.; Chi, K.H.; Pillay, A.; Nachamkin, E.; Su, J.R.; Ballard, R.C. Detection of the A2058G and A2059G
23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a
TaqMan real-time multiplex PCR assay. J. Clin. Microbiol. 2013, 51, 908–913. [CrossRef] [PubMed]
40. Šmajs, D.; Pašteˇková, L.; Grillová, L. Macrolide resistance in the syphilis spirochete, Treponema pallidum ssp.
pallidum: Can we also expect macrolide-resistant yaws strains? Am. J. Trop. Med. Hyg. 2015, 93, 678–683.
41. Šmajs, D.; Pospíšilová, P. Macrolide resistance in yaws. Lancet 2018, 391, 1555–1556. [CrossRef]
42. Mitjà, O.; Godornes, C.; Houinei, W.; Kapa, A.; Paru, R.; Abel, H.; González-Beiras, C.; Bieb, S.V.; Wangi, J.;
Barry, A.E.; et al. Re-emergence of yaws after single mass azithromycin treatment followed by targeted
treatment: A longitudinal study. Lancet Lond. Engl. 2018, 391, 1599–1607. [CrossRef]
43. Solomon, A.W.; Holland, M.J.; Alexander, N.D.E.; Massae, P.A.; Aguirre, A.; Natividad-Sancho, A.; Molina, S.;
Safari, S.; Shao, J.F.; Courtright, P.; et al. Mass treatment with single-dose azithromycin for trachoma. N. Engl.
J. Med. 2004, 351, 1962–1971. [CrossRef] [PubMed]
44. Emerson, P.M.; Burton, M.J.; Solomon, A.W.; Bailey, R.; Mabey, D.C. The SAFE strategy for trachoma control:
Using operational research for policy, and implementation. Bull. World Health Organ. 2006, 84, 613–619.
[CrossRef] [PubMed]
45. Keenan, J.D.; Bailey, R.L.; West, S.K.; Arzika, A.M.; Hart, J.; Weaver, J.; Kalua, K.; Mrango, Z.; Ray, K.J.;
Cook, C.; et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N. Engl. J. Med. 2018,
378, 1583–1592. [CrossRef] [PubMed]
46. The World Health Organization. Eradication of yaws—The Morges Strategy. Wkly. Epidemiol. Rec. 2012,
87, 189–194.
47. Marks, M.; Mitjà, O.; Fitzpatrick, C.; Asiedu, K.; Solomon, A.W.; Mabey, D.C.; Funk, S. Mathematical
modeling of programmatic requirements for yaws eradication. Emerg. Infect. Dis. 2017, 23, 22–28. [CrossRef]
[PubMed]
48. Dyson, L.; Marks, M.; Crook, O.M.; Sokana, O.; Solomon, A.W.; Bishop, A.; Mabey, D.C.W.;
Hollingsworth, T.D. Targeted treatment of yaws with household contact tracing: How much do we miss?
Am. J. Epidemiol. 2018, 187, 837–844. [CrossRef] [PubMed]
49. Marks, M.; Vahi, V.; Sokana, O.; Puiahi, E.; Pavluck, A.; Zhang, Z.; Dalipanda, T.; Bottomley, C.; Mabey, D.C.;
Solomon, A.W. Mapping the epidemiology of yaws in the Solomon Islands: A cluster randomized survey.
Am. J. Trop. Med. Hyg. 2015, 92, 129–133. [CrossRef] [PubMed]
50. Marks, M.; Vahi, V.; Sokana, O.; Chi, K.H.; Puiahi, E.; Kilua, G.; Pillay, A.; Dalipanda, T.; Bottomley, C.;
Solomon, A.W.; et al. Impact of community mass treatment with azithromycin for trachoma elimination on
the prevalence of yaws. PLoS Negl. Trop. Dis. 2015, 9, e0003988. [CrossRef] [PubMed]
51. Marks, M.; Sokanam, O.; Nachamkin, E.; Puiahi, E.; Kilua, G.; Pillay, A.; Bottomley, C.; Solomon, A.W.;
Mabey, D.C. Prevalence of active and latent yaws in the Solomon Islands 18 months after azithromycin mass
drug administration for trachoma. PLoS Negl. Trop. Dis. 2016, 10, e0004927. [CrossRef] [PubMed]
52. Abdulai, A.A.; Agana-Nsiire, P.; Biney, F.; Kwakye-Maclea, C.; Kyei-Faried, S.; Amponsa-Achiano, K.;
Simpson, S.V.; Bonsu, G.; Ohene, S.A.; Ampofo, W.K.; et al. Community-based mass treatment with
azithromycin for the elimination of yaws in Ghana—Results of a pilot study. PLoS Negl. Trop. Dis. 2018,
12, e0006303. [CrossRef] [PubMed]
53. Mitjà, O.; Houinei, W.; Moses, P.; Kapa, A.; Paru, R.; Hays, R.; Lukehart, S.; Godornes, C.; Bieb, S.V.; Grice, T.;
Siba, P.; et al. Mass treatment with single-dose azithromycin for yaws. N. Engl. J. Med. 2015, 372, 703–710.
[CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
